Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
Takeaways from roundtable discussion on Medical Affairs challenges at MAPS 2023 Global Annual Meeting
In spring 2023, CRA’s Life Sciences Practice held a roundtable discussion with Medical Affairs leaders to better understand obstacles prohibiting their teams...